Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(40%)
Results Posted
100%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
2
40%
Ph not_applicable
1
20%
Ph phase_3
1
20%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Recruiting1
Terminated1
unknown1
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
N/A1 (20.0%)

Trials by Status

recruiting120%
terminated120%
unknown120%
active_not_recruiting120%
completed120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingnot_applicable

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

NCT07466238
active_not_recruitingphase_2

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

NCT07480850
terminatedphase_1

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

NCT05494866
completedphase_3

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

NCT00446225
unknownphase_2

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

NCT04405375

Clinical Trials (5)

Showing 5 of 5 trials
NCT07466238Not Applicable

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Recruiting
NCT07480850Phase 2

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Active Not Recruiting
NCT05494866Phase 1

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Terminated
NCT00446225Phase 3

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

Completed
NCT04405375Phase 2

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5